Resectable Lung Non-Small Cell Carcinoma

Merck & Co’s – known as MSD outside the US and Canada – Keytruda (pembrolizumab) has been recommended by the National Institute of Health and Care Excellence (NICE) to treat resectable non-small cell lung cancer (NSCLC) in adults at a high risk of disease recurrence. The anti-PD-1 therapy has been specifically recommended for use in combination with platinum-based chemotherapy as a neoadjuvant treatment before surgery and then as a monotherapy in the adjuvant setting after surgery. Lung cancer is the third most common cancer in the UK and NSCLC accounts for approximately 90% of all cases. While surgery is successful for many patients with early stages of the disease, recurrence is common and the five-year survival in the UK is generally below the European average. Administered as an intravenous infusion, Keytruda works by increasing the ability of the body’s immune system to help detect and fight tumour cells. More than 5,000 patients in England are expected to be eligible for the therapy following NICE’s latest recommendation, which was supported by positive results from the phase 3 KEYNOTE-671 trial. In the study, the Keytruda regimen was associated with significant improvements in event-free survival, major pathological response, pathological complete response and overall survival compared to placebo in patients with previously untreated, resectable NSCLC. Benson Fayehun, head of oncology at MSD UK, said: “Lung cancer is the third largest cancer in the UK and as such affects many lives. [The company] is proud to share that patients now have access to a new treatment option in early-stage lung cancer… We are grateful for our collaboration with NICE and NHS England to make this possible.” Also commenting on the recommendation, Toby Talbot, consultant clinical oncologist at Royal Cornwall Hospitals, said: “This newly reimbursed treatment has been shown to reduce risk of cancer relapse following surgery and will be a valuable additional treatment for patients being treated for lung cancer.” The positive opinion comes just one week after Keytruda was approved by the Medicines and Healthcare products Regulatory Agency in combination with Astellas/Pfizer’s Padcev (enfortumab vedotin) as a first-line treatment for advanced bladder cancer. The UK regulator’s decision applies to adults with unresectable or metastatic urothelial carcinoma who are eligible for platinum-containing chemotherapy.

SHANGHAI, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, and its wholly-owned subsidiary, TopAlliance Biosciences Inc. (TopAlliance Biosciences), announce that toripalimab (Indian trade name: ZYTORVI®, Hong Kong trade name: LOQTORZI®) has been approved for marketing in India and China’s Hong Kong Special Administrative Region (“SAR”), for treatment of recurrent or metastatic nasopharyngeal carcinoma (“NPC”). The approved indications are: 1) toripalimab in combination with cisplatin and gemcitabine, for first line treatment of adults with metastatic or with recurrent, locally advanced NPC; 2) toripalimab as a single agent, for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy. Zytorvi® shall be imported and commercialized in India by Dr. Reddy’s Laboratories Ltd. Dr. Jianjun ZOU, General Manager and CEO of Junshi Biosciences, said, “As of now, toripalimab has been approved for marketing in over 30 countries and regions across three continents worldwide. With its differentiated clinical layout and outstanding clinical performance, it has brought a new treatment that can change the therapeutic landscape to local doctors and patients, which we are very excited about. Moving forward, we will continue to implement the company's international strategy of ‘In China, For Global’ and work with partners to provide more overseas patients with high-quality innovative drugs from China.” NPC is a malignant tumor that occurs in the epithelium of the nasopharynx. According to GLOBOCAN 2022 statistics, the number of newly diagnosed NPC cases in 2022 exceeded 120,000 worldwide. Due to the location of the primary tumor, surgery is rarely an option. Toripalimab is the first and only treatment for NPC approved in India and China’s Hong Kong SAR. The marketing approvals are supported by results from JUPITER-02, a randomized, double-blind, placebo-controlled, multinational multi-center Phase 3 clinical study (NCT03581786) that examined toripalimab in combination with gemcitabine-cisplatin as the first-line treatment of NPC, as well as results from POLARIS-02, a multi-center, open-label, pivotal Phase 2 clinical study (NCT02915432) that evaluated toripalimab as the second-line or later treatment for recurrent or metastatic NPC. The JUPITER-02 study is the first international multi-center, double-blind, randomized Phase III clinical study in the field of immunotherapy for NPC with the largest sample size, and the world’s first Phase III clinical study with preset statistical verification (Type I error control) for Overall Survival (“OS”) for first-line immunotherapy combined with chemotherapy for NPC compared to chemotherapy alone and demonstrated a survival benefit. The study results were presented in an oral report during the Plenary Session of the 2021 annual meeting of the American Society of Clinical Oncology (ASCO) (#LBA2) and were subsequently featured on the cover of Nature Medicine. The results were also published in full in the Journal of the American Medical Association (JAMA). The results showed that, compared to chemotherapy alone, toripalimab in combination with chemotherapy reduced the risk of disease progression by 48% and the risk of death by 37%. The median progression-free survival (“PFS”) in the toripalimab plus chemotherapy group was prolonged by 13.2 months compared to chemotherapy alone, from 8.2 months to 21.4 months. In addition, patients treated with this combined therapy achieved a higher objective response rate (ORR), longer duration of response (DoR), and no new safety signal was identified. Long-term survival follow-up data, presented at ASCO 2024, reported a 5-year survival rate of 52.0% in the toripalimab treated arm. The POLARIS-02 results were published online in January 2021 in the Journal of Clinical Oncology. The results showed that toripalimab demonstrated durable antitumor activity in patients with recurrent or metastatic NPC who failed previous chemotherapy, with an ORR of 20.5%, a DoR of 12.8 months, and a median OS of 17.4 months while maintaining a manageable safety profile. So far, toripalimab has been approved for marketing in over 30 countries and regions, including the Chinese mainland, Hong Kong SAR, the US, European Union, and India. Several marketing applications are currently under regulatory review or submitted for review in UK, Australia, Singapore, Malaysia, South Africa, Chile, Jordan, Brazil, Columbia, Philippines, Thailand and Indonesia. About Toripalimab Toripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 promotes the immune system’s ability to attack and kill tumor cells. More than forty company-sponsored toripalimab clinical studies covering more than fifteen indications have been conducted globally by Junshi Biosciences, including in China, the United States, Southeast Asia, and Europe. Ongoing or completed pivotal clinical trials evaluating the safety and efficacy of toripalimab cover a broad range of tumor types, including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney, and skin. In the Chinese mainland, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYI®). Currently, there are ten approved indications for toripalimab in the Chinese mainland: unresectable or metastatic melanoma after failure of standard systemic therapy;recurrent or metastatic nasopharyngeal carcinoma (“NPC”) after failure of at least two lines of prior systemic therapy;locally advanced or metastatic urothelial carcinoma that failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy;in combination with cisplatin and gemcitabine as the first-line treatment for patients with locally recurrent or metastatic NPC;in combination with paclitaxel and cisplatin in first-line treatment of patients with unresectable locally advanced/recurrent or distant metastatic esophageal squamous cell carcinoma (“ESCC”);in combination with pemetrexed and platinum as the first-line treatment in EGFR mutation-negative and ALK mutation-negative, unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer (“NSCLC”);in combination with chemotherapy as perioperative treatment and subsequently with monotherapy as adjuvant therapy for the treatment of adult patients with resectable stage IIIA-IIIB NSCLC;in combination with axitinib for the first-line treatment of patients with medium to high risk unresectable or metastatic renal cell carcinoma (RCC);in combination with etoposide plus platinum for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC);in combination with paclitaxel for injection (albumin-bound) for the first-line treatment of recurrent or metastatic triple-negative breast cancer (TNBC). The first six indications have been included in the National Reimbursement Drug List (NRDL) (2023 Edition). Toripalimab is the only anti-PD-1 monoclonal antibody included in the NRDL for the treatment of melanoma. In the United States, the US FDA has approved the Biologics License Application for toripalimab in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced NPC, and for toripalimab, as a single agent, for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy in October 2023. The FDA has granted toripalimab 2 Breakthrough Therapy designations for the treatment of NPC, 1 Fast Track designation for the treatment of mucosal melanoma, and 5 Orphan Drug designations for the treatment of esophageal cancer, NPC, mucosal melanoma, soft tissue sarcoma, and small cell lung cancer (SCLC). In Europe, the European Committee approved marketing authorization applications (MAA) for toripalimab 1) combined with cisplatin and gemcitabine for the first-line treatment of patients with locally recurrent or metastatic NPC and 2) combined with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced/recurrent or metastatic ESCC in September 2024. The UK Medicines and Healthcare products Regulatory Agency (MHRA) accepted the MAA in February 2023. In Australia, the new chemical entity (NCE) application was accepted by the Australia Therapeutic Goods Administration (TGA) in November 2023. The TGA has also granted toripalimab an Orphan Drug designation for the treatment of NPC. In Asia, toripalimab obtained import license from the National Regulatory Authority (NRA) of India in September 2024, and marketing approval from Pharmacy and Poisons Board of China’s Hong Kong SAR in October 2024, for the treatment of recurrent or metastatic NPC. In Singapore, the new drug application (“NDA”) application was accepted by the Singapore Health Sciences Authority (HSA) in January 2024. The HSA has also granted priority review designation for the NDA. About Junshi Biosciences Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Four of the company’s innovations have already reached the Chinese or international markets, one of which is toripalimab, China’s first domestically produced and independently developed anti-PD-1 monoclonal antibody, approved in over 30 countries and regions including China, the US, the European Union, etc. Additionally, more than 30 drugs are currently in clinical development. During the COVID-19 pandemic, Junshi Biosciences actively shouldered the social responsibilities of a Chinese pharmaceutical company through its involvement in developing etesevimab, MINDEWEI®, and other novel therapies for the prevention and treatment of COVID-19. With a mission of “providing patients with world-class, trustworthy, affordable, and innovative drugs,” Junshi Biosciences is “In China, For Global.” At present, the company boasts approximately 2,500 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc.). For more information, please visit: http://junshipharma.com. Junshi Biosciences Contact InformationIR Team:Junshi Biosciencesinfo@junshipharma.com+ 86 021-6105 8800 PR Team:Junshi BiosciencesZhi Lizhi_li@junshipharma.com+ 86 021-6105 8800

前言 AIDD Pro 根据国内外各大网站以及人工智能药物设计主流新闻网站及公众号，从 AIDD会议、AIDD招聘，重大科研进展、行业动态、最新报告发布等角度，分析挖掘了每周人工智能辅助药物设计领域所发生的、对领域技术发展产生重大推动作用的事件，旨在帮助 AIDD领域研究人员和业内人士及时追踪最新科研动态、洞察前沿热点。如果您觉得符合以上要求的内容我们有遗漏或者更好建议，欢迎后台留言。 科研进展2024年10月5日【靶向蛋白质】ACS Biomater. Sci. Eng. | DNA纳米技术在靶向蛋白质降解中的应用2024年10月4日【计算机辅助药物设计】ACS Omega | 计算机辅助药物设计和分子动力学模拟筛选小分子化合物DHPA通过靶向TrkB抑制神经母细胞瘤细胞增殖2024年10月4日【SARS-CoV-2】ACS Pharmacol. Transl. Sci. | 巯基反应性或氧化还原活性：修改重新筛选导致新的失效管道，并鉴定出针对SARS-CoV-2的木瓜蛋白酶的真正非共价抑制剂2024年10月3日【药物发现】J. Chem. Inf. Model. | 炼金术转化及超越：自由能计算在药物发现中的最新进展和实际应用2024年10月3日【抑制剂】J. Chem. Inf. Model. | AutoDesigner - Core Design：一种化学支架的从头设计算法:应用于新型选择性Wee1抑制剂的设计和合成2024年10月3日【PROTAC】J. Chem. Inf. Model. | 用终点结合自由能计算表征PROTAC体系的协同效应 具体信息，请滑动下方文字 1.【靶向蛋白质】 DNA是一种灵活、多功能的生物材料，可用于构建纳米结构和纳米器件。由于DNA纳米技术具有很高的生物相容性和可编程性，并且易于修饰和制造，因此它已成为细胞内靶向蛋白质降解的有力工具。本文综述了蛋白质水解靶向嵌合体、溶酶体靶向嵌合体和基于自噬的蛋白质降解等蛋白质靶向降解技术的设计和机制的最新进展。随后，我们介绍了DNA级联电路、DNA纳米结构和动态机器的DNA纳米技术。此外，我们还介绍了DNA纳米技术在靶向蛋白质降解方面的最新进展。最后，讨论了发展前景和面临的挑战。 链接网址：https://pubs.acs.org/doi/10.1021/acsbiomaterials.4c01351 DOI：https://doi.org/10.1021/acsbiomaterials.4c01351 2.【计算机辅助药物设计】 神经母细胞瘤是一种罕见的儿童恶性实体肿瘤。由于其异质性，给治疗带来了重大挑战，导致死亡率高。本研究旨在通过对PDB 4AT5的TrkB受体进行建模，并对YaTCM数据库(包含来自6220种中药的47,696种化合物)中的化合物进行虚拟筛选，以发现新的治疗药物。筛选利用e -药效团方法筛选与TrkB具有潜在结合亲和力的化合物。通过分子动力学模拟、拉伸动力学模拟和US模拟测试了这些化合物的结合能力。在前11个优化命中化合物中，DHPA和3″-去甲基六氢姜黄素表现突出。进一步的模拟表明它们与TrkB形成稳定的受体-配体二元配合物。在随后的体外细胞实验中，3″-去甲基六氢姜黄素因其杀死NB细胞的高IC50而被淘汰。低浓度DHPA可显著杀伤NB细胞。此外，DHPA可以抑制TrkB的表达，激活TrkB的下游信号通路，影响TrkB蛋白的热稳定性及其对streptase蛋白酶降解的反应。DHPA可能是一种潜在的TrkB抑制剂。 链接网址：https://pubs.acs.org/doi/10.1021/acsomega.4c04528 DOI：https://doi.org/10.1021/acsomega.4c04528 3.【SARS-CoV-2】 SARS-CoV-2木瓜蛋白酶样蛋白酶PLpro在病毒复制周期中具有多种作用，与其多肽切割功能和对抗宿主免疫反应的能力有关。靶向PLpro功能被认为是一种有前途的机制，可以调节病毒复制，同时支持宿主免疫反应。然而，plpro特异性抑制剂的开发仍然具有挑战性。利用酶、结合研究和细胞分析的综合研究显示，先前报道的抑制剂以非特异性方式起作用。目前，GRL-0617及其衍生物在细胞和小鼠模型中仍然是最有效的抗病毒活性化合物。在这项研究中，我们提到了PLpro氧化还原敏感性的缺陷。使用基于筛选的方法来鉴定PLpro蛋白水解活性抑制剂，我们在一系列条件和读数下验证了活性化合物，强调在分析假定的PLpro抑制剂时需要全面的正交数据。剩余的活性化合物CPI-169在基于核磁共振的实验中被证明是一种非共价抑制剂，能够与GRL-0617竞争，这表明它占据了类似的结合位点并抑制了Vero-E6细胞中的病毒复制，为进一步开发抗病毒药物开辟了新的设计机会。 链接网址：https://pubs.acs.org/doi/10.1021/acsptsci.4c00325 DOI：https://doi.org/10.1021/acsptsci.4c00325 4.【药物发现】 计算方法是筛选和优化潜在药物分子的有效策略。这个过程中的一个关键因素是候选分子和目标之间的结合亲和力，用结合自由能来量化。在各种估算方法中，炼金术变换法以其理论的严谨性脱颖而出。尽管在力场精度和采样效率方面存在挑战，但算法、软件和硬件的进步增加了自由能摄动(FEP)计算在制药工业中的应用。在这里，我们回顾了自2018年以来FEP在药物发现项目中的实际应用，包括以配体为中心和以残基为中心的转化。我们表明，在实际应用中，相对结合自由能的计算已经稳定地达到了化学精度。此外，我们还讨论了基于物理的替代模拟方法以及将深度学习纳入自由能计算的方法。 链接网址：https://pubs.acs.org/doi/10.1021/acs.jcim.4c01024 DOI：https://doi.org/10.1021/acs.jcim.4c01024 5.【抑制剂】 药物发现计划的命中识别阶段通常涉及设计具有期望生物活性的新型化学支架，以对抗感兴趣的靶标。一种常见的方法是支架跳跃，即基于已知的化学物质手工设计新的支架。这种方法的一个主要限制是狭窄的化学空间探索，这可能导致难以维持或提高生物活性，选择性和有利的属性空间。另一个限制是缺乏这些设计的初步结构-活性关系(SAR)数据，这可能导致选择次优支架来推进先导优化。为了解决这些限制，我们提出了AutoDesigner - CoreDesign (CoreDesign)，一种全新的支架设计算法。我们的方法是一种云集成的从头设计算法，用于系统地探索和提炼针对感兴趣的生物靶点的化学支架。该算法使用主动学习FEP，根据定义的项目参数，包括结构新颖性、物理化学属性、效力和选择性，设计、评估和优化范围广泛，从数百万到数十亿的硅分子。为了在现实世界的药物发现环境中验证CoreDesign，我们将其应用于设计新型有效的Wee1抑制剂，其选择性优于PLK1。CoreDesign从一个已知的配体和受体结构开始，快速探索了超过230亿个分子，确定了1342个新的化学系列，每个支架平均有4个化合物。为了快速分析大量数据并确定合成化学支架的优先级，我们使用了硅性质的t分布随机相邻嵌入(t-SNE)图。化学空间投影使我们能够快速识别结构新颖的5-5融合岩心，满足所有命中识别要求。从该支架中合成并测定了几种化合物，显示出良好的抗Wee1效力和良好的PLK1选择性。我们的研究结果表明，通过允许团队提出不受初步SAR可用性影响的高质量化学支架，CoreDesign可以显著加快命中识别过程，提高药物发现活动成功的可能性。 链接网址：https://pubs.acs.org/doi/10.1021/acs.jcim.4c01031 DOI：https://doi.org/10.1021/acs.jcim.4c01031 6.【PROTAC】 蛋白水解靶向嵌合体(Proteolytic targeting chimeras, PROTACs)是一种新兴的药物类型，它通过基于接近性的方式发挥作用，缩小靶蛋白与E3泛素连接酶之间的距离，从而促进靶蛋白的泛素化标记以进行降解。虽然已有证据表明PROTAC三元相互作用的协同性是影响目标蛋白降解率的关键因素之一，但由于目标- PROTAC - e3三元体系中相互作用的复杂性和灵活性，利用这一指标进行PROTAC设计仍然具有挑战性。因此，开发可靠、实用的计算方法对PROTAC设计具有重要意义。因此，在本研究中，我们研究了用分子力学/泊松-玻尔兹曼(广义-玻生)表面积(MM/PB(GB)SA)表示的端点结合自由能计算方法来表征PROTAC体系协同性(包括稳定化和钩效应)的可行性。结果表明，在较长的分子动力学调整(50-100 ns)和较低介电常数(εin = 1)条件下，MM/GBSA是表征这些效应的较好预测因子，稳定效应和挂钩效应的Pearson相关系数(rp)分别> 0.5和0.6。本研究为表征PROTAC系统的协同性提供了一种可行的策略，有助于PROTAC分子的合理设计。 链接网址：https://pubs.acs.org/doi/10.1021/acs.jcim.4c01227 DOI：https://doi.org/10.1021/acs.jcim.4c01227 上下滚动查看更多 药企动态2024年10月5日【百时美施贵宝】百时美施贵宝重磅免疫疗法再获FDA批准，显著降低肺癌患者复发风险2024年10月4日【阿斯利康】延长PFS近一年半，阿斯利康重磅BTK抑制剂获FDA优先审评资格2024年10月4日【赛诺菲】10.75亿美元：补体领域又一笔重大交易2024年10月4日【诺诚健华】诺诚健华「奥布替尼」治疗系统性红斑狼疮完成2期临床试验患者入组2024年10月3日【Triveni Bio】扩大免疫和炎症（I&I）管线，新锐获超1亿美元B轮融资2024年10月2日【礼来】礼来投资45亿美元新建药物开发与生产中心各动态具体信息，请滑动下方文字 1.【百时美施贵宝】 今日，美国FDA宣布，批准百时美施贵宝（Bristol Myers Squibb）开发的重磅PD-1抑制剂Opdivo（nivolumab）与含铂化疗联用作为手术前的新辅助疗法，随后单药作为手术后的辅助疗法，治疗可切除的非小细胞肺癌（NSCLC）成人患者。这些患者不携带EGFR或ALK基因变异。 链接网址请戳我 2.【阿斯利康】 今日，阿斯利康（AstraZeneca）公司宣布，为布鲁顿氏酪氨酸激酶（BTK）抑制剂Calquence（acalabrutinib）递交的补充新药申请（sNDA）已经被美国FDA接受并授予优先审评资格，用于治疗初治套细胞淋巴瘤（MCL）成人患者。 链接网址请戳我 3.【赛诺菲】 2024年10月4日，赛诺菲将补体C1s抗体药物Enjzymo的全球权益出售给意大利老牌药企Recordati，后者支付8.25亿美元预付款，2.5亿美元商业里程碑金额。 链接网址请戳我 4.【诺诚健华】 今日（10月4日），诺诚健华宣布，其研发的新型BTK抑制剂奥布替尼治疗系统性红斑狼疮（SLE）的2期临床试验完成患者入组。这是一项随机、双盲、安慰剂对照、多中心的2b期临床研究，旨在评估奥布替尼在成人SLE患者中的有效性和安全性。该研究总共入组187例患者，治疗时间为48周。 链接网址请戳我 5.【Triveni Bio】 Triveni Bio今天宣布完成1.15亿美元的B轮融资，以支持其旗下I&I管线扩展。此轮融资由Goldman Sachs Alternatives领投，其他新投资者包括Fidelity Management & Research Company和Deep Track Capital，A轮投资者Atlas Venture、Cormorant Asset Management、OrbiMed、Viking Global Investors和Invus也参与其中。值得一提的是，Triveni Bio在不到一年前时完成了一项总额达9200万美元的A轮融资。 链接网址请戳我 6.【礼来】 10月2日，礼来宣布投资 45 亿美元创建礼来药物铸造厂（Medicine Foundry），这是一个新的先进生产和药物开发中心。这一独特的设施将使礼来有能力研究新的药品生产方式，同时扩大用于临床试验的药品生产规模。作为有史以来首个将研究与生产集于一身的同类设施，Medicine Foundry将位于印第安纳州黎巴嫩的LEAP研究与创新区，并将把公司在该地区的投资扩大到130多亿美元。 链接网址请戳我 上下滚动查看更多 会议信息 2024年10月18-20日 天津市生物医药行业协会举办中国(天津)国际生物医药产业博览会 2024年10月24-25日 E药学苑举办ChemCon 2024第四届小分子药物创新开发论坛 各会议具体详情和参会方式，请滑动下方文字 中国(天津)国际生物医药产业博览会 主办方：天津市生物医药行业协会 会议时间：2024年10月18-20日 会议地点：天津 会议主旨：为贯彻落实“十四五”规划和 2035 年远景目标，加快建设高质量生物医药体系，加快推动我国生物医药产业创新升级，加强生物医药产业的交流与合作，提升企业品牌和认知度，博览会立足天津辐射全国，发挥京津冀协同发展区域优势定位于“国际化、品牌化、专业化”，推动生物医药行业高质量发展中的重要作用，加速优质项目市场布局，助力中国生物医药事业的发展，助推中国迈入生物医药强国行列。 链接网址请戳我 ChemCon 2024第四届小分子药物创新开发论坛 主办方：E药学苑 会议时间：2024年10月24-25日 会议地点：南京 会议主旨：作为目前药物研发领域的主流，小分子药物具有许多优势和挑战。为推动研发和产业化的发展，促进行业内的学术交流与合作，邀请近百名知名专家学者分享他们在小分子创新药、改良型新药等领域的科研成果以及独到见解。 链接网址请戳我 上下滚动查看更多 版权信息 本文内容均由小编收集于公开的各个网络平台，发布的目的仅为了方便大家一站式了解AIDD行业信息，并未对发布源头进行真实性验证。如您发现相关信息有任何版权侵扰或者信息错误，请及时联系AIDD Pro（请添加微信号sixiali_fox59）进行删改处理。 原创内容未经授权，禁止转载至其他平台。有问题可发邮件至sixiali@stonewise.cn 关注我，更多资讯早知道↓↓↓